Tag: Petrelintide

Clinical Data Anti-obesity Drugs Clinical Trials Healthcare & Pharmaceuticals News

Roche Obesity Portfolio Forges Ahead as Enicepatide and Petrelintide Show Landmark Phase II Efficacy

Roche News
Roche News

Roche announces groundbreaking Phase II data for enicepatide and petrelintide ahead of the ADA 2026 Scientific Sessions, positioning its pipeline for best-in-class weight loss and advanced combination therapies.

Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Roche Reports Breakthrough Phase II Results for Petrelintide in Chronic Weight Management

Roche

Roche’s investigational amylin analog, petrelintide, achieved a statistically significant 10.7% mean body weight reduction in a Phase II trial, offering a well-tolerated alternative to current obesity treatments.